

PROMETHEUS® Celiac Serology Cat. # 1155

Product Description

PROMETHEUS® Celiac Serology is a comprehensive serum antibody profile. By combining important serologic markers for diagnosing celiac disease and utilizing a 5-marker panel including deamidated gliadin peptide antibodies IgA and IgG, this test offers consistent results from a recognized leader in celiac testing.

- An evaluation of antibodies associated with celiac disease to assist physicians with diagnosis and dietary compliance.
- **Specimen Requirements** - Serum, 2.0 mL: SST or Red Top Tube.
- **Shipping and Handling** - Ambient or refrigerated.
- **Storage Conditions/Stability** - 7 days ambient; 14 days refrigerated.
- **Turn Around Time** - 2-3 business days from date of receipt.
- **Reference Range:**
 - Deamidated gliadin peptide antibody IgG ELISA: < 4.9 EU/ml
 - Deamidated gliadin peptide antibody IgA ELISA: < 6.1 EU/ml
 - Anti-human tTG IgA ELISA: <10.3 U/mL
 - Anti-endomysial IgA IFA: Negative
 - Total serum IgA: < 3 years: 8-220 mg/dL; 3-13 years: 41-395 mg/dL; >13 years: 44-441 mg/dL

Facilities Description

- Prometheus is located in San Diego, CA. **Tax ID#** 33-0685754 **NPI#** 1073642641.
- Licensed in several states including New York and California.
- Prometheus is CLIA certified and CAP accredited. All laboratory tests have been validated in accordance with the guidelines established by these and other applicable agencies. Currently, Food and Drug Administration (FDA) approval is not required for Celiac Serology testing performed by Prometheus.

CPT Codes (as applied by Prometheus)

- **83520(X3)**, ELISA; antibody specific (Deamidated gliadin peptide IgA, Deamidated gliadin peptide IgG, anti-tissue transglutaminase IgA)
- **88347**, Anti-endomysial (EMA) IgA antibody by IFA
- **82784**, Total serum IgA, by nephelometry

Literature References

- Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States. *Arch Intern Med.* 2003;163:286-292.
- Green PHR, Jabri B. Coeliac disease. *Lancet.* 2003;362(9381):383-391.
- Mothes, T., Deamidated Gliadin Peptides as Targets for Celiac Disease-Specific Antibodies; *Advances in Clinical Chem*, 2007; Vol. 44, 35-63.